What are the minimum age approvals for intravenous iron formulations?

Age Requirements for Intravenous Iron Formulations

In the United States, iron sucrose is FDA-approved from 2 years of age and iron gluconate from 6 years of age for children with chronic kidney disease, while ferric carboxymaltose is approved from 1 year of age. 1

Regulatory Approval by Formulation

United States FDA Approvals:

• Iron sucrose (Venofer): Approved from ≥2 years of age for iron deficiency anemia in chronic kidney disease 1
• Iron gluconate (Ferrlecit): Approved from ≥6 years of age for iron deficiency anemia in chronic kidney disease 1
• Ferric carboxymaltose (Injectafer): Approved from ≥1 year of age 2
• Ferric derisomaltose (Monoferric): Limited pediatric data, but case series report use in children as young as 2 years 3

European Regulatory Status:

No intravenous iron preparation is currently approved for pediatric use in Europe, though these products are nevertheless used off-label in children 1

Clinical Practice Recommendations

Preferred Formulation for Pediatric Use:

Iron sucrose is the most studied iron preparation in children with the best safety profile and is recommended for intermittent infusions in pediatric patients. 1 This recommendation is based on:

• 232 children receiving 1,624 doses with very few serious adverse reactions
• No anaphylactic reactions in a randomized study of 145 children, adolescents, and young adults
• Strong recommendation with strong consensus (LoE 3, RG 0) 1

Weight-Based Dosing for Pediatric Patients:

For hemodialysis patients (10-dose course): 4

• <10 kg: 25 mg per dose
• 10-20 kg: 50 mg per dose
• ≥20 kg: 100 mg per dose

For predialysis/peritoneal dialysis patients (single infusion): 4

• <10 kg: 125 mg total dose
• 10-20 kg: 250 mg total dose
• ≥20 kg: 500 mg total dose

Parenteral Nutrition Context:

For patients on long-term parenteral nutrition who cannot maintain adequate iron status enterally, daily parenteral iron supplementation should be: 1

• Preterm infants: 200-250 mcg/kg/day
• Infants and children: 50-100 mcg/kg/day (maximum 5 mg/day)

Critical Safety Considerations

Iron Dextran Warning:

Iron dextran carries higher risk of allergic reactions and requires a test dose before the treatment dose 1. In one pediatric series, 5 of 31 children required discontinuation due to adverse reactions 1. Iron dextran should not be the first-line choice in pediatric patients.

Dose-Related Toxicity:

One case of systemic iron toxicity with hepatocellular damage occurred in a pediatric patient receiving 16 mg/kg of iron sucrose (exceeding recommended dosing) 1. The recommended maximum single dose of iron sucrose is 300 mg 1.

Newer Formulations:

While ferric carboxymaltose has FDA approval from 1 year of age and limited pediatric data show it is well-tolerated 2, iron sucrose remains the most extensively studied and recommended formulation for routine pediatric use 1.

Practical Algorithm for Formulation Selection:

1. Age 1-2 years: Ferric carboxymaltose (FDA-approved) or iron sucrose (off-label but most studied)
2. Age 2-6 years: Iron sucrose (FDA-approved, preferred based on evidence)
3. Age ≥6 years: Iron sucrose (preferred) or iron gluconate (FDA-approved)
4. Avoid iron dextran unless other formulations unavailable due to higher reaction rates

Monitor iron status (ferritin and hemoglobin) regularly in patients requiring ongoing therapy to prevent both deficiency and overload. 1